Literature DB >> 8725727

Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver.

T Seki1, H Imai, S Uno, T Ariga, T D Gelehrter.   

Abstract

We have studied the production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in liver of normal rats and in rats with mild cirrhosis induced by carbon tetrachloride inhalation, to demonstrate the production of these fibrinolytic components and their pathophysiologic role in the liver in vivo. Immunohistochemical study of paraffin-embedded liver sections and fibrin autography of frozen sections showed that the normal rat liver produces very little t-PA or PAI-1. On the contrary, striking t-PA activity and both t-PA and PAI-1 antigens were observed in the cirrhotic liver. Both t-PA and PAI-1 in plasma were also markedly increased in the cirrhotic rats. Because the hepatocyte can internalize t-PA or PA/PAI-1 complexes from circulation, Northern blot analysis of the total liver RNA was performed to demonstrate the endogenous synthesis of t-PA and PAI in the liver. Although the normal liver hardly expresses either t-PA or PAI-1 mRNA, striking t-PA and PAI-1 mRNA expression was observed in the liver of rats with mild cirrhosis. These data demonstrate that t-PA and PAI-1 production is strongly upregulated in the liver in rats with mild cirrhosis. These fibrinolytic components, whose production is closely associated with liver failure, may play important roles in the regulation of hepatocyte proliferation and liver regeneration in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725727

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Angiostatin inhibits experimental liver fibrosis in mice.

Authors:  J Mathys Vogten; Tamas A Drixler; Elisabeth A te Velde; Marguerite E Schipper; Theo J M V van Vroonhoven; Emile E Voest; Inne H M Borel Rinkes
Journal:  Int J Colorectal Dis       Date:  2004-01-10       Impact factor: 2.571

2.  Mcp-1, eNOS, tPA and PAI-1 gene polymorphism and correlation of genotypes and phenotypes in hepatopulmonary syndrome.

Authors:  Gokhan Tumgor; Afig Berdeli; Cigdem Arikan; Ertürk Levent; Sema Aydogdu
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

3.  Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats.

Authors:  Ryuichi Noguchi; Kosuke Kaji; Tadashi Namisaki; Kei Moriya; Hideto Kawaratani; Mitsuteru Kitade; Hiroaki Takaya; Yosuke Aihara; Akitoshi Douhara; Kiyoshi Asada; Norihisa Nishimura; Toshio Miyata; Hitoshi Yoshiji
Journal:  Mol Med Rep       Date:  2020-07-28       Impact factor: 2.952

4.  Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis.

Authors:  Sung Hwan Ki; Ji Hye Yang; Sae Kwang Ku; Sang Chan Kim; Young Woo Kim; Il Je Cho
Journal:  J Ginseng Res       Date:  2013-03       Impact factor: 6.060

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.